Struggling to choose between Wegovy and Mounjaro in the UK? Learn the key differences, effectiveness, side effects, and how Weight Medics can help you achieve sustainable weight loss.
Introduction
With obesity rates rising in the UK, effective medical weight loss treatments are more in demand than ever. Two of the most talked-about options are Wegovy and Mounjaro—both weekly injectable medications shown to support significant weight loss. But which is right for you?
At Weight Medics, we specialise in doctor-led weight loss programmes, offering licensed treatments like Wegovy (semaglutide) and Mounjaro (tirzepatide). In this article, we compare both medications to help you make an informed choice.
What is Wegovy?
Wegovy is a prescription-only weight loss injection containing semaglutide, a GLP-1 receptor agonist. Originally developed for managing type 2 diabetes, it has now been licensed for weight management in adults with obesity or those who are overweight with at least one weight-related condition (e.g. high blood pressure or sleep apnoea).
Key Facts:
Dosage: Weekly injection (starting at 0.25 mg, increasing up to 2.4 mg)
Mechanism: Mimics GLP-1, a hormone that regulates appetite
Weight Loss Results: Up to 15% body weight loss in 68 weeks (STEP 1 trial, Wilding et al., 2021)
What is Mounjaro?
Mounjaro is a newer injectable medication containing tirzepatide, which mimics both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) hormones. This dual-action mechanism makes it a powerful tool in weight loss and glucose control.
Key Facts:
Dosage: Weekly injection (ranging from 2.5 mg to 15 mg)
Mechanism: Targets two hunger-regulating hormones for enhanced appetite suppression and improved metabolic control
Weight Loss Results: Up to 22.5% body weight loss (SURMOUNT-1 trial, Jastreboff et al., 2022)
At Weight Medics, we offer both medications as part of a comprehensive, doctor-supervised weight loss programme, ensuring safety, support, and sustainable results.
Which One Should You Choose?
Choosing between Wegovy and Mounjaro depends on your health profile, weight loss goals, and tolerance for side effects.
A consultation with one of our Weight Medics clinicians will help determine which option is most suitable for your individual needs.
Interestingly, The SURMOUNT-5 clinical trial showed that tirzepatide led to significantly greater weight loss compared to semaglutide in adults with obesity or overweight with at least one weight-related medical problem. Participants on tirzepatide saw an average weight reduction of 20.2% at week 72, compared to 13.7% on semaglutide. Women in the study also experienced greater weight loss on tirzepatide than men.
Expert Support at Weight Medics
At Weight Medics, our bespoke treatment plans go beyond the injection. We provide:
- Ongoing consultations with experienced clinicians
- Nutritional support and lifestyle coaching
- Regular monitoring to ensure your health and safety
Final Thoughts
Both Wegovy and Mounjaro offer transformative potential for weight loss in the UK. The key is to choose the right treatment under medical supervision.
Ready to start your weight loss journey? Book a consultation with Weight Medics today and let our experts guide you towards a healthier, more confident you.
References
Wilding, J.P.H., et al. (2021). "Once-Weekly Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine, 384(11), 989–1002. DOI: 10.1056/NEJMoa2032183
Jastreboff, A.M., et al. (2022). "Tirzepatide Once Weekly for the Treatment of Obesity." New England Journal of Medicine, 387, 205–216. DOI: 10.1056/NEJMoa2206038
NICE. (2023). "Semaglutide for managing overweight and obesity." NICE.org.uk
